Pirtobrutinib plus R-CHOP for untreated non-GCB DLBCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug called pirtobrutinib combined with standard chemotherapy (R-CHOP) for people with a type of large B-cell lymphoma that hasn't been treated before. The goal is to see if adding this drug helps the treatment work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of non-GCB diffuse large B-cell lymphoma (a specific subtype of DLBCL).
- You must be between 18 and 80 years old.
- You must not have received any previous treatment for your lymphoma.
- You must have at least one measurable tumor seen on a PET/CT scan done within 28 days before joining.
- Your overall health should be reasonably good (able to care for yourself, up and about more than half of the day).
- Your liver, kidney, heart, and blood counts must be within acceptable ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of targeted therapy (pirtobrutinib) with standard chemotherapy (Pola-R-CHP) for people newly diagnosed with a type of large B-cell lymphoma that is not the germinal center B-cell subtype. The goal is to see if adding pirtobrutinib helps the treatment work better.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a targeted drug called zanubrutinib combined with standard chemotherapy (R-CHOP) for people with DLBCL who have specific genetic changes in their tumor. The goal is to see if adding this drug can improve outcomes.
This trial tests if adding orelabrutinib (a targeted pill) to standard chemotherapy, with or without a stem cell transplant, works better for people with a new diagnosis of diffuse large B-cell lymphoma. It may help patients who have a higher risk of the lymphoma coming back.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
This trial tests a new targeted therapy, Rocbrutinib, for a specific type of aggressive B-cell lymphoma (non-GCB DLBCL) that has not responded to or returned after two or more prior treatments. It aims to see if Rocbrutinib can help people who have few other options.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.